Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CABA NASDAQ:ETHZ NASDAQ:KYTX NASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$2.69-1.1%$3.14$1.26▼$4.23$438.62M3.264.44 million shs1.66 million shsETHZFlag Ship Acquisition$5.73+1.1%$5.25$0.70▼$17.46$108.94M1.176.44 million shs144,402 shsKYTXKyverna Therapeutics$7.41+1.6%$8.27$2.80▼$13.67$450.49M1.871.14 million shs850,743 shsPRTAProthena$8.75+2.6%$9.15$6.58▼$11.80$458.09M-0.31487,452 shs576,837 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio0.00%-4.95%-7.88%-8.81%+68.13%ETHZFlag Ship Acquisition+1.06%+0.88%+13.02%+17.66%+572,999,900.00%KYTXKyverna Therapeutics0.00%-0.54%-9.63%-18.21%+71.13%PRTAProthena0.00%+1.04%-5.61%-18.60%+29.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$2.69-1.1%$3.14$1.26▼$4.23$438.62M3.264.44 million shs1.66 million shsETHZFlag Ship Acquisition$5.73+1.1%$5.25$0.70▼$17.46$108.94M1.176.44 million shs144,402 shsKYTXKyverna Therapeutics$7.41+1.6%$8.27$2.80▼$13.67$450.49M1.871.14 million shs850,743 shsPRTAProthena$8.75+2.6%$9.15$6.58▼$11.80$458.09M-0.31487,452 shs576,837 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio0.00%-4.95%-7.88%-8.81%+68.13%ETHZFlag Ship Acquisition+1.06%+0.88%+13.02%+17.66%+572,999,900.00%KYTXKyverna Therapeutics0.00%-0.54%-9.63%-18.21%+71.13%PRTAProthena0.00%+1.04%-5.61%-18.60%+29.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCABACabaletta Bio 2.57Moderate Buy$15.50476.21% UpsideETHZFlag Ship Acquisition 1.00SellN/AN/AKYTXKyverna Therapeutics 2.67Moderate Buy$30.00304.86% UpsidePRTAProthena 2.75Moderate Buy$23.75171.43% UpsideCurrent Analyst Ratings BreakdownLatest ETHZ, CABA, PRTA, and KYTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026PRTAProthena UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/24/2026PRTAProthena HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.007/17/2026CABACabaletta Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/9/2026PRTAProthena Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026KYTXKyverna Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026PRTAProthena Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026CABACabaletta Bio Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026KYTXKyverna Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/2/2026PRTAProthena Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026CABACabaletta Bio Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$2.00 ➝ $4.005/15/2026KYTXKyverna Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $25.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCABACabaletta BioN/AN/AN/AN/A$1.16 per shareN/AETHZFlag Ship Acquisition$4.11M26.50N/AN/A$29.12 per share0.20KYTXKyverna TherapeuticsN/AN/AN/AN/A$3.85 per shareN/APRTAProthena$9.68M47.32N/AN/A$5.21 per share1.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCABACabaletta Bio-$167.86M-$1.96N/AN/AN/AN/A-131.58%-96.46%8/6/2026 (Estimated)ETHZFlag Ship Acquisition-$6.17M-$159.65N/AN/AN/AN/A-185.71%-83.12%N/AKYTXKyverna Therapeutics-$161.31M-$3.28N/AN/AN/AN/A-81.88%-64.87%8/11/2026 (Estimated)PRTAProthena-$244.09M-$2.82N/AN/A1.40-260.92%-43.44%-36.87%8/3/2026 (Estimated)Latest ETHZ, CABA, PRTA, and KYTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026KYTXKyverna Therapeutics-$0.67N/AN/AN/AN/AN/A8/6/2026Q2 2026CABACabaletta Bio-$0.37N/AN/AN/A$1.67 millionN/A8/3/2026Q2 2026PRTAProthena-$0.39N/AN/AN/A$0.42 millionN/A5/14/2026Q1 2026CABACabaletta Bio-$0.41-$0.39+$0.02-$0.39$1.67 millionN/A5/12/2026Q1 2026KYTXKyverna Therapeutics-$0.75-$0.66+$0.09-$0.66N/AN/A5/7/2026Q1 2026PRTAProthena-$0.31$0.60+$0.91$0.60$0.81 million$51.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCABACabaletta BioN/AN/AN/AN/AN/AETHZFlag Ship AcquisitionN/AN/AN/AN/AN/AKYTXKyverna TherapeuticsN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCABACabaletta BioN/A2.952.95ETHZFlag Ship Acquisition1.1110.0710.07KYTXKyverna Therapeutics0.138.158.15PRTAProthenaN/A10.4310.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCABACabaletta BioN/AETHZFlag Ship Acquisition4.07%KYTXKyverna Therapeutics18.08%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipCABACabaletta Bio6.44%ETHZFlag Ship Acquisition15.10%KYTXKyverna Therapeutics17.60%PRTAProthena10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCABACabaletta Bio50163.05 million152.55 millionOptionableETHZFlag Ship Acquisition719.01 million16.14 millionN/AKYTXKyverna Therapeutics9660.79 million50.10 millionOptionablePRTAProthena13052.35 million46.91 millionOptionableETHZ, CABA, PRTA, and KYTX HeadlinesRecent News About These CompaniesProthena (NASDAQ:PRTA) Stock Rating Lowered by Wall Street ZenJuly 25 at 1:30 AM | americanbankingnews.comProthena (NASDAQ:PRTA) Downgraded by Wall Street Zen to "Hold"July 25 at 1:29 AM | marketbeat.comProthena (NASDAQ:PRTA) Share Price Passes Below 200-Day Moving Average - Time to Sell?July 22, 2026 | marketbeat.comProthena (NASDAQ:PRTA) Share Price Passes Below Two Hundred Day Moving Average - What's Next?July 14, 2026 | marketbeat.comPRTA Stock Rises Nearly 11% in Six Months: What's Driving It?July 9, 2026 | zacks.comProthena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative DiseasesJune 26, 2026 | finance.yahoo.comSRPT or PRTA: Which Is the Better Value Stock Right Now?June 24, 2026 | zacks.comProthena (NASDAQ:PRTA) Major Shareholder William Scully Buys 20,000 Shares of StockJune 19, 2026 | insidertrades.comInsider Buying: Prothena (NASDAQ:PRTA) Major Shareholder Acquires 125,000 Shares of StockJune 13, 2026 | insidertrades.comProthena (NASDAQ:PRTA) Major Shareholder Acquires $465,500.00 in StockJune 6, 2026 | insidertrades.comWilliam Scully Buys 50,000 Shares of Prothena (NASDAQ:PRTA) StockJune 4, 2026 | insidertrades.comWilliam Scully Purchases 100,000 Shares of Prothena (NASDAQ:PRTA) StockMay 27, 2026 | insidertrades.comProthena Corp. PlcMay 19, 2026 | edition.cnn.comPiper Sandler Sticks to Its Buy Rating for Prothena (PRTA)May 14, 2026 | theglobeandmail.comProthena (PRTA) Gets a Hold from RBC CapitalMay 14, 2026 | theglobeandmail.comEarnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsMay 12, 2026 | finance.yahoo.comProthena: Q1 Earnings SnapshotMay 8, 2026 | wtop.comWProthena Posts Q1 Earnings as Revenues Surge on Milestone PaymentMay 8, 2026 | zacks.comProthena Reports First Quarter 2026 Financial Results and Business HighlightsMay 7, 2026 | businesswire.comProthena to Report First Quarter 2026 Financial Results on May 7April 30, 2026 | businesswire.comProthena announces Novo Nordisk obtains fast track designation from the US FDA for Coramitug (PRX004) in ATTR amyloidosis with cardiomyopathyApril 27, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETHZ, CABA, PRTA, and KYTX Company DescriptionsCabaletta Bio NASDAQ:CABA$2.69 -0.03 (-1.10%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.70 +0.01 (+0.37%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Flag Ship Acquisition NASDAQ:ETHZ$5.73 +0.06 (+1.06%) As of 07/24/20261180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.Kyverna Therapeutics NASDAQ:KYTX$7.41 +0.12 (+1.65%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$7.41 0.00 (0.00%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Prothena NASDAQ:PRTA$8.75 +0.22 (+2.58%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$8.90 +0.15 (+1.77%) As of 07/24/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
